Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The B-cell lymphoma 2 (Bcl-2) family consists of evolutionarily conserved proteins that serve as the primary regulators of the intrinsic (mitochondrial) pathway of apoptosis [1, 13, 23]. This family is structurally and functionally divided into three groups: anti-apoptotic proteins (e.g., BCL-2, BCL-XL, MCL-1), pro-apoptotic effector proteins (BAX and BAK), and pro-apoptotic BH3-only initiator proteins (e.g., BIM, PUMA, BAD) [5, 12, 15]. These members interact through their Bcl-2 homology (BH) domains to function as a molecular rheostat, governing the integrity of the mitochondrial outer membrane [13, 15, 20]. When pro-apoptotic signals prevail, BAX and BAK undergo oligomerization to cause mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c and subsequent cell death [7, 11, 20]. In many diseases, particularly cancer, the balance of the Bcl-2 family is disrupted through the overexpression of anti-apoptotic members or the loss of pro-apoptotic ones, allowing cells to evade programmed death and resist therapy [1, 4, 18, 21]. This biological dependence makes them high-priority therapeutic targets, leading to the development of BH3 mimetics such as venetoclax [1, 4, 10, 15]. These small-molecule drugs competitively bind to the hydrophobic grooves of anti-apoptotic proteins, displacing pro-apoptotic "activators" to trigger apoptosis specifically in malignant cells [7, 12, 14, 26]. Clinical application of these agents has significantly improved outcomes in hematological malignancies, though challenges like tumor lysis syndrome and acquired resistance through BCL2 mutations remain prominent [4, 8, 10, 24].
BH3 mimetics that competitively inhibit anti-apoptotic BCL-2 family members by binding to their hydrophobic grooves, thereby displacing pro-apoptotic proteins to trigger mitochondrial outer membrane permeabilization (MOMP) and subsequent apoptosis.
12 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell lymphoma 2 family (Bcl-2 family) (Bcl-2 family).